 Cory Christiansen
Concepts (289)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Limbs | 37 | 2026 | 215 | 9.350 |
Why?
| | Walking | 39 | 2026 | 549 | 6.570 |
Why?
| | Gait | 27 | 2026 | 317 | 6.010 |
Why?
| | Amputees | 22 | 2026 | 101 | 5.810 |
Why?
| | Arthroplasty, Replacement, Knee | 18 | 2025 | 383 | 5.080 |
Why?
| | Exercise | 20 | 2025 | 2219 | 3.720 |
Why?
| | Osteoarthritis, Knee | 16 | 2025 | 284 | 3.570 |
Why?
| | Exercise Therapy | 15 | 2025 | 489 | 3.410 |
Why?
| | Lower Extremity | 21 | 2026 | 452 | 3.170 |
Why?
| | Veterans | 19 | 2026 | 1675 | 3.120 |
Why?
| | Tibia | 11 | 2025 | 177 | 2.440 |
Why?
| | Walk Test | 8 | 2024 | 82 | 2.140 |
Why?
| | Resistance Training | 3 | 2025 | 186 | 2.120 |
Why?
| | Movement | 12 | 2025 | 293 | 2.070 |
Why?
| | Muscle Strength | 13 | 2026 | 336 | 1.980 |
Why?
| | Femur | 10 | 2026 | 261 | 1.930 |
Why?
| | Multiple Sclerosis | 6 | 2024 | 491 | 1.900 |
Why?
| | Parkinson Disease | 10 | 2025 | 613 | 1.830 |
Why?
| | Aged | 80 | 2026 | 26514 | 1.820 |
Why?
| | Middle Aged | 95 | 2026 | 36821 | 1.820 |
Why?
| | Telerehabilitation | 6 | 2026 | 50 | 1.800 |
Why?
| | Biomechanical Phenomena | 32 | 2026 | 873 | 1.790 |
Why?
| | Range of Motion, Articular | 14 | 2025 | 440 | 1.720 |
Why?
| | Activities of Daily Living | 8 | 2026 | 449 | 1.690 |
Why?
| | Recovery of Function | 14 | 2026 | 724 | 1.690 |
Why?
| | Osteoarthritis, Hip | 4 | 2025 | 49 | 1.640 |
Why?
| | Knee Joint | 13 | 2025 | 439 | 1.530 |
Why?
| | Accidental Falls | 5 | 2025 | 231 | 1.480 |
Why?
| | Torso | 6 | 2021 | 36 | 1.430 |
Why?
| | Accelerometry | 8 | 2025 | 126 | 1.400 |
Why?
| | Weight-Bearing | 11 | 2026 | 187 | 1.350 |
Why?
| | Self-Management | 3 | 2024 | 204 | 1.260 |
Why?
| | Male | 90 | 2026 | 73950 | 1.240 |
Why?
| | Disability Evaluation | 7 | 2023 | 312 | 1.240 |
Why?
| | Arthroplasty, Replacement, Hip | 6 | 2026 | 187 | 1.240 |
Why?
| | Prosthesis Design | 8 | 2026 | 363 | 1.140 |
Why?
| | Female | 89 | 2026 | 80076 | 1.120 |
Why?
| | Humans | 124 | 2026 | 147293 | 1.110 |
Why?
| | Hip Joint | 8 | 2026 | 173 | 1.100 |
Why?
| | Resilience, Psychological | 2 | 2021 | 157 | 1.080 |
Why?
| | Self Efficacy | 4 | 2025 | 422 | 1.050 |
Why?
| | Telemedicine | 4 | 2025 | 978 | 1.040 |
Why?
| | Health Behavior | 5 | 2024 | 799 | 1.030 |
Why?
| | Osseointegration | 10 | 2025 | 60 | 0.930 |
Why?
| | Muscle, Skeletal | 8 | 2025 | 1798 | 0.920 |
Why?
| | Task Performance and Analysis | 3 | 2024 | 203 | 0.920 |
Why?
| | Cross-Sectional Studies | 20 | 2026 | 6011 | 0.910 |
Why?
| | Postural Balance | 7 | 2026 | 254 | 0.880 |
Why?
| | Joints | 2 | 2026 | 106 | 0.860 |
Why?
| | Biofeedback, Psychology | 3 | 2025 | 35 | 0.800 |
Why?
| | Single-Blind Method | 6 | 2024 | 319 | 0.800 |
Why?
| | Aged, 80 and over | 23 | 2025 | 8430 | 0.780 |
Why?
| | Mobility Limitation | 3 | 2018 | 67 | 0.770 |
Why?
| | Exercise Test | 9 | 2024 | 636 | 0.690 |
Why?
| | Pelvis | 2 | 2020 | 129 | 0.670 |
Why?
| | Signaling Lymphocytic Activation Molecule Family | 1 | 2021 | 7 | 0.670 |
Why?
| | Tobacco Smoking | 1 | 2021 | 28 | 0.660 |
Why?
| | Physical Therapy Modalities | 5 | 2020 | 346 | 0.650 |
Why?
| | Feasibility Studies | 7 | 2025 | 1147 | 0.640 |
Why?
| | Adult | 37 | 2026 | 41405 | 0.610 |
Why?
| | Mechanical Phenomena | 1 | 2020 | 80 | 0.600 |
Why?
| | Prosthesis Implantation | 7 | 2024 | 156 | 0.580 |
Why?
| | Bone Density | 4 | 2018 | 493 | 0.570 |
Why?
| | Teriparatide | 1 | 2018 | 10 | 0.570 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2018 | 25 | 0.570 |
Why?
| | Randomized Controlled Trials as Topic | 8 | 2026 | 1776 | 0.560 |
Why?
| | Hip | 3 | 2025 | 57 | 0.530 |
Why?
| | Patient Reported Outcome Measures | 4 | 2025 | 506 | 0.510 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 567 | 0.460 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 479 | 0.450 |
Why?
| | Walking Speed | 1 | 2016 | 53 | 0.440 |
Why?
| | Behavior Therapy | 1 | 2018 | 297 | 0.440 |
Why?
| | Multimorbidity | 2 | 2026 | 66 | 0.430 |
Why?
| | Loneliness | 2 | 2025 | 69 | 0.420 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 736 | 0.420 |
Why?
| | Quadriceps Muscle | 4 | 2024 | 120 | 0.420 |
Why?
| | Peripheral Vascular Diseases | 1 | 2015 | 105 | 0.420 |
Why?
| | Postoperative Period | 4 | 2025 | 351 | 0.410 |
Why?
| | Arthralgia | 1 | 2015 | 61 | 0.410 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2025 | 38 | 0.410 |
Why?
| | Genome-Wide Association Study | 1 | 2021 | 1496 | 0.400 |
Why?
| | Diabetic Angiopathies | 3 | 2019 | 267 | 0.370 |
Why?
| | Pain | 3 | 2026 | 794 | 0.350 |
Why?
| | Quality of Life | 7 | 2026 | 3246 | 0.350 |
Why?
| | Patient Satisfaction | 5 | 2025 | 718 | 0.350 |
Why?
| | Wearable Electronic Devices | 2 | 2025 | 75 | 0.340 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 6164 | 0.310 |
Why?
| | Oxygen Consumption | 2 | 2025 | 721 | 0.280 |
Why?
| | Muscle Stretching Exercises | 1 | 2008 | 19 | 0.270 |
Why?
| | Preoperative Period | 2 | 2025 | 150 | 0.270 |
Why?
| | Bone Density Conservation Agents | 3 | 2015 | 82 | 0.270 |
Why?
| | Ankle | 1 | 2008 | 69 | 0.260 |
Why?
| | Dependent Ambulation | 2 | 2019 | 11 | 0.260 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2018 | 2627 | 0.260 |
Why?
| | Disease Progression | 2 | 2015 | 2890 | 0.260 |
Why?
| | Pain Measurement | 4 | 2026 | 569 | 0.250 |
Why?
| | Case-Control Studies | 5 | 2021 | 3660 | 0.240 |
Why?
| | Phenotype | 1 | 2015 | 3216 | 0.240 |
Why?
| | Phantom Limb | 1 | 2026 | 8 | 0.230 |
Why?
| | Amputation Stumps | 1 | 2026 | 14 | 0.230 |
Why?
| | Pilot Projects | 2 | 2024 | 1912 | 0.230 |
Why?
| | Retrospective Studies | 11 | 2025 | 17560 | 0.230 |
Why?
| | Kinetics | 2 | 2020 | 1569 | 0.220 |
Why?
| | Social Support | 2 | 2020 | 655 | 0.220 |
Why?
| | Patient Compliance | 3 | 2020 | 591 | 0.220 |
Why?
| | Calcitonin | 2 | 2015 | 27 | 0.220 |
Why?
| | Synovitis | 2 | 2015 | 35 | 0.210 |
Why?
| | Equivalence Trials as Topic | 1 | 2024 | 35 | 0.200 |
Why?
| | Treatment Outcome | 10 | 2025 | 11947 | 0.200 |
Why?
| | Cohort Studies | 4 | 2021 | 6099 | 0.200 |
Why?
| | Leg | 2 | 2016 | 243 | 0.200 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3448 | 0.200 |
Why?
| | Confidence Intervals | 2 | 2018 | 330 | 0.190 |
Why?
| | Functional Laterality | 1 | 2024 | 241 | 0.190 |
Why?
| | Patient Participation | 2 | 2024 | 449 | 0.190 |
Why?
| | Double-Blind Method | 6 | 2025 | 2080 | 0.190 |
Why?
| | Exercise Tolerance | 1 | 2025 | 289 | 0.180 |
Why?
| | Low Back Pain | 1 | 2024 | 109 | 0.180 |
Why?
| | Cumulative Trauma Disorders | 1 | 2022 | 30 | 0.180 |
Why?
| | Regional Blood Flow | 1 | 2024 | 514 | 0.180 |
Why?
| | Peripheral Arterial Disease | 2 | 2019 | 510 | 0.170 |
Why?
| | Qualitative Research | 3 | 2025 | 1735 | 0.170 |
Why?
| | Prospective Studies | 5 | 2025 | 8164 | 0.170 |
Why?
| | Stair Climbing | 1 | 2021 | 6 | 0.170 |
Why?
| | United States | 5 | 2026 | 16313 | 0.160 |
Why?
| | CpG Islands | 1 | 2021 | 176 | 0.160 |
Why?
| | Smokers | 1 | 2021 | 139 | 0.150 |
Why?
| | Evaluation Studies as Topic | 1 | 2020 | 164 | 0.150 |
Why?
| | United Kingdom | 1 | 2021 | 391 | 0.150 |
Why?
| | Time Factors | 4 | 2025 | 7173 | 0.150 |
Why?
| | Cross-Over Studies | 2 | 2025 | 617 | 0.150 |
Why?
| | Decision Support Techniques | 1 | 2024 | 480 | 0.150 |
Why?
| | Mammography | 1 | 2000 | 172 | 0.140 |
Why?
| | Proof of Concept Study | 1 | 2019 | 90 | 0.140 |
Why?
| | Computer Simulation | 2 | 2026 | 1018 | 0.140 |
Why?
| | Risk Factors | 6 | 2025 | 11017 | 0.140 |
Why?
| | Sulfonylurea Compounds | 1 | 2018 | 51 | 0.140 |
Why?
| | Placebos | 1 | 2018 | 193 | 0.140 |
Why?
| | Heart Rate | 3 | 2025 | 860 | 0.130 |
Why?
| | Patient Discharge | 1 | 2025 | 1002 | 0.130 |
Why?
| | Thiazolidinediones | 1 | 2018 | 143 | 0.130 |
Why?
| | Diet, Reducing | 1 | 1998 | 91 | 0.130 |
Why?
| | Self-Assessment | 1 | 2018 | 75 | 0.130 |
Why?
| | High-Intensity Interval Training | 1 | 2018 | 45 | 0.130 |
Why?
| | User-Computer Interface | 1 | 1998 | 165 | 0.130 |
Why?
| | Radiography | 3 | 2015 | 862 | 0.130 |
Why?
| | Feedback | 1 | 2017 | 181 | 0.120 |
Why?
| | Psychometrics | 1 | 2021 | 739 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 583 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 708 | 0.120 |
Why?
| | Ulna | 1 | 1996 | 35 | 0.120 |
Why?
| | Amputation, Traumatic | 1 | 2016 | 21 | 0.110 |
Why?
| | Bone and Bones | 1 | 2018 | 322 | 0.110 |
Why?
| | Postmenopause | 1 | 1998 | 394 | 0.110 |
Why?
| | Posture | 1 | 2017 | 197 | 0.110 |
Why?
| | Spine | 1 | 2017 | 184 | 0.110 |
Why?
| | Radius | 1 | 1996 | 53 | 0.110 |
Why?
| | DNA Methylation | 1 | 2021 | 722 | 0.110 |
Why?
| | Knee Prosthesis | 1 | 2015 | 30 | 0.110 |
Why?
| | Acceleration | 1 | 2015 | 36 | 0.110 |
Why?
| | Perception | 1 | 2018 | 378 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 329 | 0.110 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2012 | 41 | 0.110 |
Why?
| | Research Design | 2 | 2020 | 1157 | 0.100 |
Why?
| | Synovial Membrane | 1 | 2015 | 128 | 0.100 |
Why?
| | Models, Biological | 2 | 2026 | 1772 | 0.100 |
Why?
| | Cognition Disorders | 1 | 1998 | 551 | 0.100 |
Why?
| | Psychomotor Performance | 1 | 2016 | 326 | 0.100 |
Why?
| | Motivation | 1 | 2018 | 615 | 0.100 |
Why?
| | Face | 1 | 2015 | 176 | 0.100 |
Why?
| | Lumbar Vertebrae | 1 | 1996 | 259 | 0.100 |
Why?
| | Cartilage, Articular | 2 | 2015 | 349 | 0.100 |
Why?
| | Torque | 1 | 2013 | 82 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2009 | 285 | 0.100 |
Why?
| | Brain Injuries | 1 | 1998 | 508 | 0.100 |
Why?
| | Patient Safety | 1 | 2017 | 356 | 0.090 |
Why?
| | Osteoarthritis | 1 | 2015 | 204 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2018 | 625 | 0.090 |
Why?
| | Antirheumatic Agents | 1 | 2015 | 308 | 0.090 |
Why?
| | Thigh | 1 | 2012 | 48 | 0.090 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2973 | 0.090 |
Why?
| | Peptide Fragments | 2 | 2015 | 698 | 0.090 |
Why?
| | Parathyroid Hormone | 1 | 2012 | 118 | 0.090 |
Why?
| | Proteins | 1 | 1998 | 1024 | 0.090 |
Why?
| | Mass Screening | 1 | 2000 | 1375 | 0.090 |
Why?
| | Reference Values | 2 | 2013 | 800 | 0.080 |
Why?
| | Precision Medicine | 1 | 2015 | 464 | 0.080 |
Why?
| | Comorbidity | 1 | 2016 | 1672 | 0.080 |
Why?
| | Heart Failure | 1 | 2024 | 2334 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 1003 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1431 | 0.070 |
Why?
| | Prognosis | 2 | 2015 | 4383 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1415 | 0.070 |
Why?
| | Metatarsophalangeal Joint | 1 | 2008 | 11 | 0.070 |
Why?
| | Etidronic Acid | 1 | 2007 | 3 | 0.070 |
Why?
| | Linear Models | 3 | 2013 | 852 | 0.070 |
Why?
| | Incidence | 1 | 2015 | 2954 | 0.070 |
Why?
| | Ambulatory Care Facilities | 1 | 2010 | 269 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2000 | 2420 | 0.060 |
Why?
| | Collagen Type I | 3 | 2015 | 145 | 0.060 |
Why?
| | Hepatitis C | 1 | 2010 | 256 | 0.060 |
Why?
| | Fractures, Spontaneous | 1 | 2007 | 15 | 0.060 |
Why?
| | C-Reactive Protein | 2 | 2022 | 430 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2218 | 0.060 |
Why?
| | Body Mass Index | 1 | 2015 | 2470 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2015 | 3980 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1302 | 0.060 |
Why?
| | Anger | 1 | 2025 | 61 | 0.050 |
Why?
| | Collagen Type II | 2 | 2015 | 53 | 0.050 |
Why?
| | Obesity | 1 | 1998 | 3149 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2025 | 3027 | 0.050 |
Why?
| | Aging | 1 | 2015 | 1992 | 0.050 |
Why?
| | Osteoporosis | 1 | 2007 | 239 | 0.050 |
Why?
| | Mental Recall | 1 | 2026 | 225 | 0.050 |
Why?
| | Canada | 1 | 2025 | 435 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 347 | 0.050 |
Why?
| | Foot | 1 | 2024 | 109 | 0.050 |
Why?
| | Antiparkinson Agents | 1 | 2022 | 41 | 0.050 |
Why?
| | Knee | 1 | 2023 | 73 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.050 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 59 | 0.040 |
Why?
| | Biomarkers | 4 | 2015 | 4351 | 0.040 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2022 | 155 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2026 | 793 | 0.040 |
Why?
| | Goals | 1 | 2023 | 186 | 0.040 |
Why?
| | Administration, Oral | 2 | 2015 | 874 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 417 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2025 | 932 | 0.040 |
Why?
| | Sampling Studies | 1 | 2000 | 98 | 0.040 |
Why?
| | False Positive Reactions | 1 | 2000 | 124 | 0.040 |
Why?
| | Physical Examination | 1 | 2022 | 245 | 0.040 |
Why?
| | Health Maintenance Organizations | 1 | 2000 | 105 | 0.040 |
Why?
| | Community-Based Participatory Research | 1 | 2021 | 174 | 0.040 |
Why?
| | Needs Assessment | 1 | 2022 | 409 | 0.040 |
Why?
| | Focus Groups | 1 | 2022 | 587 | 0.040 |
Why?
| | Clinical Clerkship | 1 | 2000 | 109 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 134 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 1998 | 165 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1998 | 52 | 0.030 |
Why?
| | Risk | 1 | 2000 | 927 | 0.030 |
Why?
| | Odds Ratio | 1 | 2000 | 1084 | 0.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 85 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2030 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 199 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 789 | 0.030 |
Why?
| | Self Report | 1 | 2021 | 887 | 0.030 |
Why?
| | Propensity Score | 1 | 2018 | 379 | 0.030 |
Why?
| | Leptin | 1 | 1998 | 249 | 0.030 |
Why?
| | Models, Statistical | 1 | 2000 | 677 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1046 | 0.030 |
Why?
| | Peptides | 2 | 2015 | 1003 | 0.030 |
Why?
| | Facial Muscles | 1 | 2015 | 5 | 0.030 |
Why?
| | Cheek | 1 | 2015 | 16 | 0.030 |
Why?
| | Subcutaneous Tissue | 1 | 2015 | 26 | 0.030 |
Why?
| | Students, Medical | 1 | 2000 | 380 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2000 | 594 | 0.030 |
Why?
| | Eyelids | 1 | 2015 | 41 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1344 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2000 | 2133 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 1996 | 277 | 0.030 |
Why?
| | Collagen Type III | 1 | 2013 | 15 | 0.030 |
Why?
| | Body Composition | 1 | 1998 | 694 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2016 | 563 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2013 | 95 | 0.020 |
Why?
| | Isometric Contraction | 1 | 2013 | 190 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2015 | 646 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 794 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 849 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 430 | 0.020 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 14 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 528 | 0.020 |
Why?
| | Urban Health | 1 | 2010 | 96 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2012 | 1371 | 0.020 |
Why?
| | Hepacivirus | 1 | 2010 | 243 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1998 | 5476 | 0.020 |
Why?
| | Bone Resorption | 1 | 2007 | 81 | 0.020 |
Why?
| | Area Under Curve | 1 | 2007 | 334 | 0.010 |
Why?
| | Hip Fractures | 1 | 2007 | 88 | 0.010 |
Why?
| | Inflammation | 1 | 2015 | 2920 | 0.010 |
Why?
| | Adolescent | 2 | 2015 | 22825 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2889 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10194 | 0.010 |
Why?
| | Massachusetts | 1 | 2000 | 181 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 12016 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3372 | 0.010 |
Why?
| | Teaching | 1 | 2000 | 242 | 0.010 |
Why?
| | Risk Assessment | 1 | 2007 | 3784 | 0.010 |
Why?
| | Child | 1 | 2015 | 22979 | 0.010 |
Why?
| | Primary Health Care | 1 | 2000 | 1759 | 0.000 |
Why?
|
|
Christiansen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|